

Sino-Swiss Pitchinar: Selected Swiss biotech startups pitch to Chinese investors and enterprises

30.09.2021 07:30, Isabelle Mitchell

For the third time, the China-Switzerland Innovation and Entrepreneurship Pitchinar showcased the two countries' innovation potential and fostered the exchange between Swiss and Chinese startups. The Swiss startup delegation comprised selected Swiss biotech startups—including the Venture Leaders Biotech 2021. The pitchinar also provided online matchmaking opportunities to strengthen relationships and facilitate collaborations. The program was hosted by the China Science and Technology Exchange Center (CSTEC), the Science and Technology Commission of Shanghai Municipality, and Venturelab.

The pitchinar began with welcoming speeches by renowned experts and leaders: Gao Xiang (Director General, China Science and Technology Exchange Center), Olivier Zehnder (Consul General, Consulate General of Switzerland in Shanghai), Zhuang Jia (Deputy Director General, China Science and Technology Exchange Center), Xie Wenlan (Vice Chairman, Science and Technology Commission of Shanghai Municipality), Didier Vuarnoz (Director of Science, Technology and Education Division, Embassy of Switzerland in China), and Stefan Steiner (Co-Managing Director, Venturelab).



The goal of the pitchinar—boosting the bilateral connections—was illustrated with a presentation of selected cooperation cases between China and Switzerland. These relationships demonstrated the countries' innovative ambitions and potential to grow through collaboration and knowledge exchange.



“The collaboration between China and Switzerland continues to grow stronger every year. The Sino-Swiss Pitchinar provides entrepreneurs with exposure and allows them to connect with Chinese and Swiss partners and investors,” said Stefan Steiner, co-managing director at Venturelab and one of the hosts of the pitchinar. “For the [Venture Leaders Biotech](#), this is a great opportunity to advance their global ambitions and strengthen their networks.”

Swiss Biotech Startups

Group 1



Swiss Biotech Startups

Group 2




1

World-class Startups. Swiss made.

7

World-class Startups. Swiss made.

Ten Chinese and ten Swiss startups pitched their innovations and answered questions for an international audience that included entrepreneurs, investors, and industry experts. “We thank Venturelab for the opportunity to participate in the China-Switzerland Pitchinar 2021. This event turned out to be extremely useful to reach out and interact with potential Chinese investors. The pitchinar also revealed the breadth and depth of the extraordinary biotech research in China, an imminent hotbed for innovation in the coming decade,” said Rajesh Jayachandran, co-founder and CSO of [NextImmune](#). Fellow Venture Leader Biotech Awa Diagne, the co-founder and CEO of [Nemosia](#) added: “The pitchinar has been a unique platform for us not only to present our venture but also to start the discussion with one of the world-leading PET/CET research centers working on neurodegeneration. We foresee great collaboration opportunities in clinical development activities.”



To stay up to date on the Venture Leaders Biotech, follow the hashtag [#VLeadersBiotech](#) on social media.

CSTEC supports Swiss startups in China beyond the pitchinar: For the second time, CSTECC produced and distributed the Chinese version of the [TOP 100 Swiss Startup Magazine](#).

Learn more about the ten Swiss startups that participated in the pitchinar:

4D Lifetec AG: Liquid Biopsy Assay for early cancer detection

4D Lifetec AG is a highly innovative Swiss start up founded 2014 by Dr. Arne Faisst and Nick Mijnsen. We have set up an experienced motivated team of experts to create a footprint in the world of can... [Read more](#)

Acthera Therapeutics AG: Next generation drug delivery for almost any drug modality

ACTHERA Ltd. incorporated in 2019 in Basel is developing an entirely novel targeted therapy technology based on Hard-Shelled Liposomes (HSLs). The proprietary technology has the potential to address t... [Read more](#)

Avrion Therapeutics AG: Precision gene therapies for neurological disorders

Avrion Therapeutics is a spin-off from EPFL developing precision gene therapy solutions to address genetically defined neurological disorders. Gene therapies can provide benefit through modulation of ... [Read more](#)

cellvie AG: From cells to medicine

cellvie is bringing about a new treatment modality, leveraging the therapeutic potential of mitochondria. Specifically, it was shown that mitochondria, the powerhouses of the cell, can be augmented an... [Read more](#)

deepCDR Biologics AG: Deep learning in antibody discovery and engineering

We harness the power of machine learning to move beyond experimental screening found in traditional therapeutic antibody discovery and engineering processes. To achieve this, we combine three state-of-the-art... [Read more](#)

HexagonFab AG: Low-cost drug discovery tools

Designing, developing and commercializing nanomaterial-based biosensors for life science analysis that require high-sensitive, rapid and real-time results (e.g. protein interaction analysis). [Read more](#)

Nemosia: The missing link in the fight against neurodegeneration!

At Nemosia, we aim to raise public awareness of neurological disorders and promote a culture where it is seen as normal and safe to do regular brain check-ups even if there are no visible symptoms. We... [Read more](#)

NextImmune AG: Novel Therapy for Autoimmunity and Organ Transplantation.

NextImmune, is a spin-off from the Biozentrum, University of Basel, and is focused on the research and development of a novel class of immunosuppressive therapies for autoimmune-inflammatory diseases ... [Read more](#)

Resistell AG: Revolutionary alternative for antibiotic susceptibility testing

SEPSIS is a life-threatening reaction to infection with over 50 million cases and 11 million related deaths worldwide. Resistell's breakthrough patented technology delivers AST diagnostic results in hours... [Read more](#)